21 Nov 2018

BOSTON SCIENTIFIC ACQUIRING BTG

    Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders

0
08 Nov 2018

VIVA 2018: BTG SENTRY BIOCONVERTIBLE IVC FILTER STUDY SHOWS FLAWLESS PERFORMANCE

  BTG plc highlighted the presentation of the two-year results for the SENTRY Trial at the Vascular Interventional Advances (VIVA) conference in Las Vegas. The prospective, multicenter trial of the BTG Sentry, the world’s first bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism (PE) during the

0
28 Jul 2018

POLIDOCANOL INJECTABLE FOAM: WHEN VEINS DON’T TAKE A STRAIGHT PATH

Patient presents with bilateral bulging varicosities   By Ajit Naidu, MD An estimated one-third of the population in Western countries has untreated venous disease.[i] Some of these individuals have lived with debilitating symptoms of venous insufficiency for a decade or more because their primary care physicians or OB/GYNs have told

0
07 Jun 2018

OPTALYSE PE: BTG RESULTS REINFORCE SAFETY, EFFICACY OF SHORTER, LOWER DOSE EKOS THERAPY FOR PE

BTG plc highlighted OPTALYSE PE one-year trial results, presented at the International Society on Endovascular Therapy in Florida in February. The findings confirm that bilateral pulmonary embolism (PE) patients treated in as little as two hours with a total tissue plasminogen activator (tPA) dose as low as 8mg continue to

0
10 Apr 2018

VARITHENA IS AN ELEGANT SOLUTION FOR C6 ULCER

At 4 months post-treatment, Tom’s wound remained closed and he stated that he was very satisfied with the treatment.     By Kenneth Otah, MD, MSc, FACC Patients with venous ulcers make up over up more than 70 percent of nonhealing ulcers. By the time these patients are referred to

0